In our Perspectives article (The case for uric acid- lowering treatment in patients with hyperuricaemia and CKD. Nat. Rev. Nephrol.15, 767–775; 2019)1 we proposed that individuals with hyperuricaemia and chronic kidney disease (CKD) with wors-ening kidney function should be consid-ered for urate- lowering therapy (ULT) to 422 | July 2020 | volume 16 CorrespondenCewww.nature.com/nrneph slow progression of CKD1. When review-ing the literature, we argued that a trial was only interpretable if the control group showed clinically meaningful worsening of kidney function, which we defined as a reduction in estimated glomerular filtration rate (eGFR) of at least 4–5 ml/min/1.73 m2.
Yuka Sato, D.I.F. (2020). Reply to 'The case for evidence-based medicine for the association between hyperuricaemia and CKD'. NATURE REVIEWS. NEPHROLOGY, 16(7), 422-423 [10.1038/s41581-020-0289-2].
Reply to 'The case for evidence-based medicine for the association between hyperuricaemia and CKD'
Claudio Borghi;
2020
Abstract
In our Perspectives article (The case for uric acid- lowering treatment in patients with hyperuricaemia and CKD. Nat. Rev. Nephrol.15, 767–775; 2019)1 we proposed that individuals with hyperuricaemia and chronic kidney disease (CKD) with wors-ening kidney function should be consid-ered for urate- lowering therapy (ULT) to 422 | July 2020 | volume 16 CorrespondenCewww.nature.com/nrneph slow progression of CKD1. When review-ing the literature, we argued that a trial was only interpretable if the control group showed clinically meaningful worsening of kidney function, which we defined as a reduction in estimated glomerular filtration rate (eGFR) of at least 4–5 ml/min/1.73 m2.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
